Skip to main content

Table 2 Event Incidence and Hazard Ratios with 95% Confidence Intervals for IPTW Analysis of the Rivaroxaban and Warfarin Cohorts Using an Intent-To-Treat Approach

From: Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis

 Rivaroxaban
N = 2097
n (%)
Warfarin
N = 2842
n (%)
HR (95%CI)
3-Month
 Composite of recurrent venous thromboembolism or major bleeding96 (4.58)130 (4.57)1.08 (0.82–1.42)
 Recurrent venous thromboembolism74 (3.53)96 (3.38)1.07 (0.78–1.46)
 Major bleeding27 (1.29)40 (1.41)1.19 (0.72–1.97)
 Intracranial hemorrhage2 (0.10)5 (0.18)0.66 (0.12–3.59)
 Gastrointestinal bleeding17 (0.81)24 (0.84)1.16 (0.61–2.21)
 Genitourinary bleeding4 (0.19)6 (0.21)1.08 (0.30–3.93)
6-Month
 Composite of recurrent venous thromboembolism or major bleeding105 (5.01)166 (5.84)0.96 (0.75–1.24)
 Recurrent venous thromboembolism81 (3.86)115 (4.05)1.01 (0.76–1.36)
 Major bleeding30 (1.43)59 (2.08)0.93 (0.59–1.47)
 Intracranial hemorrhage2 (0.10)7 (0.25)0.50 (0.10–2.50)
 Gastrointestinal bleeding18 (0.86)37 (1.30)0.84 (0.47–1.51)
 Genitourinary bleeding4 (0.19)9 (0.32)0.80 (0.24–2.63)
12-Month
 Composite of recurrent venous thromboembolism or major bleeding122 (5.82)208 (7.32)0.93 (0.74–1.16)
 Recurrent venous thromboembolism89 (4.24)140 (4.93)0.95 (0.72–1.2)
 Major bleeding39 (1.86)80 (2.81)0.92 (0.62–1.36)
 Intracranial hemorrhage5 (0.24)13 (0.46)0.76 (0.27–2.19)
 Gastrointestinal bleeding21 (1.00)47 (1.65)0.80 (0.47–1.37)
 Genitourinary bleeding5 (0.24)10 (0.35)0.88 (0.29–2.63)
  1. CI Confidence interval, HR Hazard ratio, N Number